ReShape Lifesciences Inc. has entered into an Equity Distribution Agreement with Maxim Group LLC to act as the exclusive sales agent for the issuance and sale of up to $9.7 million of the company's common stock. These shares will be offered in an at-the-market public offering, utilizing the company's existing shelf registration statement. The agreement allows for sales through methods defined under Rule 415 of the Securities Act of 1933, as well as privately negotiated transactions. Maxim Group will receive a 3.0% commission on the gross proceeds from the sales. The agreement includes provisions for reimbursement of legal expenses and allows for termination by either party under specified terms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.